Eva Schaefer-Jansen | IR Officer |
Paul Hudson | CEO & Director |
Thomas Triomphe | EVP & Head of, Pasteur |
Olivier Charmeil | EVP, General Medicines |
Julie Van Ongevalle | EVP & Head, Consumer Healthcare |
John Reed | EVP & Global Head, Research & Development |
Jean-Baptiste de Chatillon | EVP & CFO |
William Sibold | EVP, Sanofi Genzyme & President, Sanofi North America |
Peter Verdult | Citigroup |
Wimal Kapadia | Sanford C. Bernstein & Co. |
Jo Walton | Crédit Suisse |
Geoffrey Porges | SVB Leerink |
Graham Parry | Bank of America Merrill Lynch |
Mark Purcell | Morgan Stanley |
Laura Sutcliffe | UBS |
Peter Welford | Jefferies |
Seamus Fernandez | Guggenheim Securities |
Luisa Hector | Berenberg |
Keyur Parekh | Goldman Sachs Group |
[Technical Difficulty] followed by a Q&A session.
As usual, you can find the slides to this earnings call on the Investors page of our website at sanofi.com.
Moving to Slide 2. I would like to remind you that information presented in this call contain forward-looking statements that involve known and unknown risks, uncertainties and other factors that may cause actual results to differ materially. I refer you to our Form 20-F document on file with the SEC and also our Document d'Enregistrement Universel for a description of these risk factors.